MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze PGNY →
    • FindStock Picks / Stock Screener
    • Value · PGNYIntrinsic Value Calculator
    • Invest · PGNYInvestment Case
    • Hold · PGNY5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
PGNY stock logo

PGNY

Progyny, Inc.

$35.71
0.26
 (0.73%)
Exchange:  NASDAQ
Market Cap:  2.63B
Shares Outstanding:  85.232M
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Medical – Healthcare PlansView industry performance
   
CEO:  Pete Anevski
Full Time Employees:  846
Address: 
1359 Broadway
New York City
NY
10018
US
Website:  https://www.progyny.com
Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.

Click to read more…

Revenue Segmentation

Revenue by type

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
PGPGNY logoPGNYProgyny, Inc.2.6B31.527.119.9%
CLCLOV logoCLOVClover Health Investments, Corp.2.0B29262.23.1%
ALALHC logoALHCAlignment Healthcare, Inc.1.3B52.3—7.2%
OSOSCR logoOSCROscar Health, Inc.6.4B11.210.532.5%
MOMOH logoMOHMolina Healthcare, Inc.10.4B—37.72.1%
CNCNC logoCNCCentene Corp.31.6B24.112.11.9%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/11/04 — 3 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue1,088,5981,167,2211,288,661
Gross Profit238,799253,363304,484
EBITDA72,97286,377100,380
Operating Income62,18467,45585,277
Net Income62,03754,33658,520

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets756,620607,102742,435
Total Liabilities203,191185,040226,391
Total Stockholders Equity553,429422,062516,044
Total Debt19,39019,27224,000
Cash and Cash Equivalents97,296162,314112,238

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow188,814179,105210,192
Capital Expenditure-3,644-5,405-18,410
Free Cash Flow185,170173,700191,782
Net Income62,03754,33658,520
Net Change in Cash-22,78265,018-48,121

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)1,758,384.961Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)1,788,682.122Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)1,772,187.033Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)228,526.295Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)233,469.259Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)230,778.102Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)182,430.787Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)186,527.370Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)184,297.018Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)293,293.177Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)298,346.650Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)295,595.320Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)2.060Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)2.080Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)2.040Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)4Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)5Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
1.167B  ?P/S
 (TTM)
: 
1.99
?Net Income
 (TTM)
: 
54.336M  ?P/E
 (TTM)
: 
31.46
?Enterprise Value
 (TTM)
: 
2.569B  ?EV/FCF
 (TTM)
: 
11.72
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
19.98%  ?ROIC
 (TTM)
: 
19.86%
?Net Debt
 (TTM)
: 
-208.682M  ?Debt/Equity
 (TTM)
: 
0.05
?P/B
 (TTM)
: 
6.66  ?Current Ratio
 (TTM)
: 
1.93

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
27.05Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates PGNY intrinsic value between $11.05 – $18.05 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate PGNY Intrinsic Value

Common questions about PGNY valuation

Is Progyny, Inc. (PGNY) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Progyny, Inc. (PGNY) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is PGNY a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether PGNY trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is PGNY’s P/E ratio?

You can see PGNY’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for PGNY?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is PGNY a good long-term investment?

Whether PGNY fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Progyny, Inc.

  • Progyny, Inc. intrinsic value calculatorEstimate what the business is worth
  • Progyny, Inc. 5-year outlookWhat has to go right, and what could go wrong
PGNY

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0.73
MarketSnap

Trading Metrics:

Open: 35.51   Previous Close: 35.45
Day Low: 35.5   Day High: 36.07
Year Low: 16.1   Year High: 37.21
Price Avg 50: 29.24   Price Avg 200: 25.08
Volume: 1.107M   Average Volume: 1.102M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

Progyny (PGNY) Upgraded to Strong Buy: What Does It Mean for the Stock?
19-11-2026 13:01
Progyny (PGNY) Upgraded to Strong Buy: What Does It Mean for the Stock?
Progyny, Inc. (PGNY) Hits Fresh High: Is There Still Room to Run?
17-11-2026 10:15
Progyny, Inc. (PGNY) Hits Fresh High: Is There Still Room to Run?
Progyny (PGNY) Is Up 3.85% in One Week: What You Should Know
16-11-2026 13:01
Progyny (PGNY) Is Up 3.85% in One Week: What You Should Know
Progyny, Inc. (PGNY) Q3 2026 Earnings Call Transcript
04-11-2026 21:04
Progyny, Inc. (PGNY) Q3 2026 Earnings Call Transcript
Progyny (PGNY) Tops Q3 Earnings and Revenue Estimates
04-11-2026 18:16
Progyny (PGNY) Tops Q3 Earnings and Revenue Estimates
New Progyny Study Examines Persistent Racial and Ethnic Differences in Fertility Treatment Initiation Despite Access to Benefits
28-10-2026 09:51
New Progyny Study Examines Persistent Racial and Ethnic Differences in Fertility Treatment Initiation Despite Access to Benefits

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Pricing

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze PGNY →
    • FindStock Picks / Stock Screener
    • Value · PGNYIntrinsic Value Calculator
    • Invest · PGNYInvestment Case
    • Hold · PGNY5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Plans
    • Settings
    • Public profile ↗
  • Log in
  • Log out

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.